Trial Profile
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs JKB 122 (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- Sponsors Jenken Biosciences; TaiwanJ Pharmaceuticals
- 31 Mar 2018 Status changed from active, no longer recruiting to discontinued as the trial completed stage I without pursuing stage II
- 31 Mar 2018 Status changed from active, no longer recruiting to discontinued as the trial completed stage I without pursuing stage II
- 03 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.